MedTrace Logo

IBI363 Combined With Bevacizumab for Advanced Colorectal Cancer

NCT07722494 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 550

Last updated 2026-08-10

No results posted yet for this study

Summary

This is an open-label, multicenter Phase 3 study to evaluate the safety and tolerability of IBI363 plus bevacizumab in patients with advanced colorectal cancer refractory or intolerant to standard-of-care therapy

Conditions

Interventions

DRUG

IBI363 + bevacizumab

In this arm, patients will receive IBI363 plus bevacizumab

DRUG

Investigator's choice of therapy

In this arm, patients will receive Fruquintinib or Trifluridine and Tipiracil Hydrochloride or Regorafenib

Sponsors & Collaborators

  • Innovent Biologics (Suzhou) Co. Ltd.

    lead INDUSTRY

Principal Investigators

  • Kefeng Ding, Medical Doctor · Second Affiliated Hospital, Zhejiang University, School of Medicine

  • Tao Zhang, Medical Doctor · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

  • Ying Yuan, Medical Doctor · Second Affiliated Hospital, Zhejiang University, School of Medicine

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-07-31
Primary Completion
2028-10-31
Completion
2030-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07722494 on ClinicalTrials.gov